Egalet announces patent for its abuse-deterrence platform

Egalet ($EGLT) announced that its Guardian abuse-deterrence and drug delivery platform has been granted an additional patent by the U.S. Patent and Trademark Office. The patent is titled "Pharmaceutical Compositions Resistant to Abuse." It is the 14th U.S. patent covering the Guardian platform and its candidates. "This patent expands our intellectual property portfolio protecting products using our proprietary abuse-deterrent Guardian Technology," said Egalet CEO Bob Radie. "We will continue to strengthen our patent position covering our products which in some cases extends to 2033 to support our organic growth." According to the company website, "Guardian Technology utilizes injection molding to create a hard matrix and shell that is designed to be difficult to crush, grind, chew or dissolve and that turns to gel when exposed to water." Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.